VEGF gene polymorphism and response to intravitreal ranibizumab in neovascular age-related macular degeneration.

doi:10.1159/000354328

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

VEGF gene polymorphism and response to intravitreal ranibizumab in neovascular age-related macular degeneration.

Ophthalmic research - 1 Jan 2014

Veloso Carlos Eduardo dos Reis, de Almeida Luciana Negrão Frota, Recchia Franco Maria, Pelayes David, Nehemy Márcio Bittar

Abstract excerpt

BACKGROUND/AIMS: To investigate the association between VEGF gene polymorphism and response to ranibizumab in neovascular age-related macular degeneration (AMD). METHODS: A total of 92 patients were genotyped for the VEGF rs1413711 single nucleotide polymorphism. Patients with neovascular AMD initially received 3 monthly ranibizumab intravitreal injections and were retreated as needed. Visual acuity (VA) and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Analysis of Variance

Share to Angiogenesis Inhibitors

Share to Antibodies, Monoclonal, Humanized

Share to Intravitreal Injections

Share to Macular Degeneration

Share to Vascular Endothelial Growth Factor A

Share to Visual Acuity

Source

Open in PubMed

Identifiers

PMID: 24157918
DOI: 10.1159/000354328

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

VEGF gene polymorphism and response to intravitreal ranibizumab in neovascular age-related macular degeneration.PMID 24157918Read ↗

Polymorphisms in vascular endothelial growth factor receptor 2 are associated with better response rates to ranibizumab treatment in age-related macular degeneration.Semantic proximity Read ↗

Predictive value of VEGF A and VEGFR2 polymorphisms in the response to intravitreal ranibizumab treatment for wet AMD.Semantic proximity Read ↗

Genetic factors associated with response to intravitreal ranibizumab in Korean patients with neovascular age-related macular degeneration.Semantic proximity Read ↗

VEGF-A polymorphisms predict short-term functional response to intravitreal ranibizumab in exudative age-related macular degeneration.Semantic proximity Read ↗

VEGFA and VEGFR2 gene polymorphisms and response to anti-vascular endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT).Semantic proximity Read ↗

Genetic association with response to intravitreal ranibizumab for neovascular age-related macular degeneration in the Han Chinese population.Semantic proximity Read ↗

Pharmacogenetic associations with long-term response to anti-vascular endothelial growth factor treatment in neovascular AMD patients.Semantic proximity Read ↗

Association between VEGF-A and VEGFR-2 polymorphisms and response to treatment of neovascular AMD with anti-VEGF agents: a meta-analysis.Semantic proximity Read ↗

Common variant in VEGFA and response to anti-VEGF therapy for neovascular age-related macular degeneration.Semantic proximity Read ↗

A genetic variant in NRP1 is associated with worse response to ranibizumab treatment in neovascular age-related macular degeneration.Semantic proximity Read ↗

Genetic influences on the outcome of anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration.Semantic proximity Read ↗

Variants in the VEGFA gene and treatment outcome after anti-VEGF treatment for neovascular age-related macular degeneration.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.